Johnson & Johnson $JNJ Stake Trimmed by Hourglass Capital LLC

Hourglass Capital LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 48.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,260 shares of the company's stock after selling 4,000 shares during the quarter. Hourglass Capital LLC's holdings in Johnson & Johnson were worth $1,128,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its holdings in Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares during the last quarter. Amundi grew its position in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company's stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Janus Henderson Group PLC grew its position in Johnson & Johnson by 1.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company's stock worth $1,924,323,000 after purchasing an additional 148,497 shares in the last quarter. Finally, Jupiter Topco LLC bought a new stake in Johnson & Johnson in the 2nd quarter worth about $1,967,399,000. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Leerink Partners decreased their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating for the company in a research note on Wednesday, October 14th. UBS Group set a $270.00 target price on Johnson & Johnson in a research note on Wednesday, October 14th. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a report on Monday, August 3rd. Guggenheim reaffirmed a "buy" rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Finally, JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $275.92.

Insider Activity

In other news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. The trade was a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 64,515 shares of company stock valued at $17,271,766 in the last 90 days. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 0.9%

Shares of JNJ stock opened at $271.17 on Thursday. The company has a 50 day moving average of $265.60 and a 200-day moving average of $246.26. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07. The firm has a market cap of $652.78 billion, a P/E ratio of 41.09, a PEG ratio of 2.61 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the prior year, the business earned $2.80 earnings per share. Johnson & Johnson's revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson's payout ratio is presently 81.21%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is included among pharmaceutical companies with potential arthritis-treatment growth, supported by drug sales, clinical progress and regulatory expansion. This reinforces the outlook for its Innovative Medicine business and future cash generation. The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
• Positive Sentiment: The company will hold an Enterprise Business Review on December 8, when management is expected to provide additional detail on its Innovative Medicine and MedTech pipelines, long-term strategy and growth opportunities. The event could offer catalysts if the company raises confidence in future earnings. Johnson & Johnson to Host Enterprise Business Review
• Neutral Sentiment: JNJ has gained roughly 97% over three years, prompting investors to assess whether its valuation is supported by expected cash flow. Oncology trial developments and MedTech performance could materially influence that assessment. Johnson & Johnson Stock Trades At A Discount Following Its 97% Run
• Negative Sentiment: Ongoing attention to a talc-related charge adds legal and cash-flow uncertainty, while investors continue to monitor the broader talc litigation overhang. What Does the Talc Charge Mean for Johnson & Johnson Going Forward?
• Negative Sentiment: Reports of approximately $34.7 million in net ETF selling represent a modest technical headwind, although such flows do not necessarily reflect a change in JNJ’s fundamentals. Johnson & Johnson Sees $34.7 Million in Net ETF Selling
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of JNJ investors. The announcement does not establish wrongdoing, but it adds to headline and litigation risk. Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Johnson & Johnson

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.